Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
AZITRA INC (AZTR)
AMEXHealth CareBiotechnologySnapshot 2026-11-05
$0.73-11.11%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AZTR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise capital through PIPE financing and private placements | The company raised capital through PIPE financing to support development. | Intact | Failure to secure planned capital raises in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative development-stage biotech, not an established earnings compounder. The multi-year thesis is in watch status: management reports program activity, but losses continue and the supplied evidence shows no revenue or clinical outcome data.
The valuation model indicates AZTR is cheap versus peers, but confidence in that comparison is low. The evidence does not say what specific growth or success expectations the market already assumes, and no valuation fragility gates fired.
Near term, continued operating losses and no reported revenue leave the business dependent on development progress; the latest supplied quarterly loss was lower than the prior quarter. Management reports ATR-04 enrollment across six sites and further preclinical findings for ATR-COSF, but clinical outcomes and a human cosmetic study remain unreported. Near-term earnings miss risk is elevated, and the recent litigation filing adds a company-specific concern.
The multi-year thesis depends on whether ATR-04 advances from enrollment to useful clinical results and whether ATR-COSF reaches a human cosmetic study. Near term, a guidance cut or further weakening in jobs data could weigh on the setup, while stronger results and guidance from healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, AZTR's case rests on turning early program progress into verifiable clinical and commercial milestones, while managing ongoing losses and execution risk. The evidence remains limited and confidence is low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Azitra aims to advance clinical trials with topline data in 2026. |
| Intact |
| Failure to report topline data for key trials by end of 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Control and reduce operating losses | Operating losses were about $3.9 million in 2026-Q1, showing ongoing investment. | Broken | Operating loss worsens beyond -$3.93 million or remains flat over next 4 quarters | Operating income: $-3.419M FY2026-Q2; GAAP. Published target: Operating loss improves from -$3.93 million in 2026-Q1 toward less negative levels. Target period is not explicitly aligned with this observation. Aug 12, 2026-3,419,168 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.10 → $-0.64 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.10 | Unavailable | 1 / 0 |
| 2026-07-25 | $-0.10 | Unavailable | 1 / 0 |
| 2026-07-26 | $-0.10 | Unavailable | 1 / 0 |
| 2026-07-27 | $-0.10 | $0 | 2 / 2 |
| 2026-07-28 | $-0.10 | $0 | 2 / 2 |
| 2026-07-29 | $-0.10 | $0 | 2 / 2 |
| 2026-07-30 | $-0.10 | $0 | 2 / 2 |
| 2026-07-31 | $-0.10 | $0 | 2 / 2 |
| 2026-08-01 | $-0.10 | Unavailable | 1 / 0 |
| 2026-08-02 | $-0.10 | Unavailable | 1 / 0 |
| 2026-08-03 | $-0.10 | $0 | 2 / 2 |
| 2026-08-04 | $-0.10 | $0 | 2 / 2 |
| 2026-08-05 | $-0.10 | $0 | 2 / 2 |
| 2026-08-06 | $-0.10 | $0 | 2 / 2 |
| 2026-08-07 | $-0.10 | Unavailable | 1 / 0 |
| 2026-08-08 | $-0.10 | $0 | 2 / 2 |
| 2026-08-09 | $-0.10 | $0 | 2 / 2 |
| 2026-08-10 | $-0.10 | $0 | 2 / 2 |
| 2026-08-11 | $-0.10 | $0 | 2 / 2 |
| 2026-08-12 | $-0.10 | $0 | 2 / 2 |
| 2026-08-13 | $-0.10 | $0 | 2 / 2 |
| 2026-08-14 | $-0.10 | Unavailable | 1 / 0 |
| 2026-08-15 | $-0.10 | Unavailable | 1 / 0 |
| 2026-08-16 | $-0.10 | Unavailable | 1 / 0 |
| 2026-08-17 | $-0.10 | Unavailable | 1 / 0 |
| 2026-08-18 | $-0.10 | Unavailable | 1 / 0 |
| 2026-08-19 | $-0.10 | Unavailable | 1 / 0 |
| 2026-08-20 | $-0.10 | Unavailable | 1 / 0 |
| 2026-08-21 | $-0.10 | Unavailable | 1 / 0 |
| 2026-08-22 | $-0.08 | Unavailable | 1 / 0 |
| 2026-08-23 | $-0.08 | Unavailable | 1 / 0 |
| 2026-08-24 | $-0.08 | Unavailable | 1 / 0 |
| 2026-08-25 | $-0.08 | Unavailable | 1 / 0 |
| 2026-08-26 | $-0.08 | Unavailable | 1 / 0 |
| 2026-08-27 | $-0.08 | Unavailable | 1 / 0 |
| 2026-08-28 | $-0.08 | Unavailable | 1 / 0 |
| 2026-08-29 | $-0.08 | Unavailable | 1 / 0 |
| 2026-08-30 | $-0.08 | Unavailable | 1 / 0 |
| 2026-08-31 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-01 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-02 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-03 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-04 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-05 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-06 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-07 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-08 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-09 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-10 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-11 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-12 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-13 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-14 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-15 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-16 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-17 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-18 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-19 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-20 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-21 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-22 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-23 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-24 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-25 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-26 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-27 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-28 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-29 | $-0.08 | Unavailable | 1 / 0 |
| 2026-09-30 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-01 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-02 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-03 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-04 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-05 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-06 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-07 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-08 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-09 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-10 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-11 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-12 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-13 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-14 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-15 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-16 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-17 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-18 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-19 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-20 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-21 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-22 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-23 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-24 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-25 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-26 | $-0.06 | Unavailable | 1 / 0 |
| 2026-10-27 | $-0.60 | Unavailable | 1 / 0 |
| 2026-10-28 | $-0.60 | Unavailable | 1 / 0 |
| 2026-10-29 | $-0.60 | Unavailable | 1 / 0 |
| 2026-10-30 | $-0.60 | Unavailable | 1 / 0 |
| 2026-10-31 | $-0.60 | Unavailable | 1 / 0 |
| 2026-11-01 | $-0.60 | Unavailable | 1 / 0 |
| 2026-11-02 | $-0.60 | Unavailable | 1 / 0 |
| 2026-11-03 | $-0.60 | Unavailable | 1 / 0 |
| 2026-11-04 | $-0.64 | Unavailable | 1 / 0 |
| 2026-11-05 | $-0.64 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.